Revolution Medicines stock snapshot

Revolution Medicines (RVMD) has drawn fresh attention after recent share price moves, with the stock last closing at $163.68 and showing sizable gains over the past month and past 3 months.

Beyond the latest move, Revolution Medicines has shown strong momentum, with a 30 day share price return of 17.35% and a 90 day share price return of 62.88%, alongside a 1 year total shareholder return above 300%. This indicates that investors have rapidly re-rated the stock in a short space of time.

If you are assessing opportunities in high growth healthcare and biotech, it can be useful to see what else is moving via our screener of 40 healthcare AI stocks.

With Revolution Medicines now trading at $163.68, a market value of about $33.5b and an intrinsic value estimate implying a sizeable discount, investors have to ask: is there still an opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 22.4% Overvalued

At a last close of $163.68 versus a most followed fair value estimate of $133.70, the current price sits well above that narrative anchor, which is built around aggressive growth, rich future margins and a premium earnings multiple.

The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.

Eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients create multiple data points over the next few years that could change how investors view the durability and scale of the pipeline, with potential implications for future revenue visibility and earnings power.

Curious what kind of revenue ramp, margin uplift and future P/E multiple are backing that $133.70 fair value, and how much dilution is baked in, before you compare it to today’s $163.68 price tag.

Result: Fair Value of $133.70 (OVERVALUED)

However, this story still hinges on Revolution Medicines turning a large current loss into future earnings while executing across multiple late stage RAS trials without major setbacks.

Another View: Cash Flows Point a Different Way

Analyst narratives put fair value at $133.70 and flag Revolution Medicines as 22.4% overvalued at $163.68. Yet the SWS DCF model, which prices the stock using future cash flow assumptions, points to a fair value of $601.39. This suggests a very different risk reward balance. Which story is closer to how you view the business.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between optimism and caution, it makes sense to look at the data yourself and decide quickly where you stand based on the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Revolution Medicines has caught your eye, do not stop there. Use the broader data to quickly spot other opportunities that could fit your portfolio.

• Target potential value by scanning 47 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect their underlying strength.
• Prioritise resilience by reviewing 62 resilient stocks with low risk scores that score well on financial health and business stability.
• Get ahead of the crowd by checking a screener containing 22 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.